ArticleJAMA network open2025

Receipt of PARP Inhibitors in Patients With Metastatic Prostate Cancer Harboring BRCA1/2 Alterations.

Micah Ostrowski et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.